Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Average Recommendation of “Buy” by Brokerages

Scholar Rock Holding Corporation (NASDAQ:SRRK) has earned a consensus rating of “Buy” from the eighteen analysts that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and five have given a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $56.00.

Several brokerages have weighed in on SRRK. Raymond James Financial restated a “strong-buy” rating on shares of Scholar Rock in a research note on Tuesday, March 3rd. Wedbush raised their target price on shares of Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a research note on Wednesday, April 1st. Piper Sandler raised their target price on shares of Scholar Rock from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, March 4th. HC Wainwright raised their target price on shares of Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, JPMorgan Chase & Co. raised their target price on shares of Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, March 16th.

Insider Buying and Selling

In other Scholar Rock news, insider Mo Qatanani sold 8,484 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $47.07, for a total value of $399,341.88. Following the completion of the sale, the insider directly owned 98,445 shares in the company, valued at $4,633,806.15. This trade represents a 7.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Keith Woods sold 10,220 shares of Scholar Rock stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $506,605.40. Following the sale, the chief operating officer owned 620,055 shares of the company’s stock, valued at $30,736,126.35. The trade was a 1.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 102,736 shares of company stock valued at $4,977,900 over the last quarter. Insiders own 13.30% of the company’s stock.

Institutional Investors Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently made changes to their positions in SRRK. IFP Advisors Inc lifted its stake in shares of Scholar Rock by 294.1% during the fourth quarter. IFP Advisors Inc now owns 603 shares of the company’s stock worth $27,000 after buying an additional 450 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Scholar Rock during the fourth quarter worth $30,000. Summit Securities Group LLC acquired a new stake in shares of Scholar Rock during the fourth quarter worth $31,000. Ramirez Asset Management Inc. acquired a new stake in shares of Scholar Rock during the third quarter worth $37,000. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after buying an additional 525 shares during the period. 91.08% of the stock is currently owned by institutional investors and hedge funds.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $49.35 on Tuesday. The firm has a market cap of $5.91 billion, a price-to-earnings ratio of -13.75 and a beta of 0.70. The company’s 50 day moving average is $46.66 and its 200 day moving average is $43.77. The company has a quick ratio of 6.95, a current ratio of 8.64 and a debt-to-equity ratio of 0.71. Scholar Rock has a 52-week low of $27.07 and a 52-week high of $51.63.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the prior year, the firm earned ($0.67) EPS. On average, sell-side analysts anticipate that Scholar Rock will post -3.18 EPS for the current fiscal year.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).